Contact Rachel

Speaking Engagements

  

Revolutionizing Genetic Therapy Development & Delivery to the Eye The Race Is On; Luxturna Remains the Only Approved Gene Therapy for the Eye, Who Will Be the Next? The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced i

13-16 September 2022
  

The field of complement-based drug development is experiencing growth due to several factors. Firstly, there is an increasing recognition of the role of the complement system in a wider range of diseases. Additionally, there is a better understanding of the molecular components of the complement system, which has revealed more targets for drug deve

11-13 September 2023